Patent · US Active

Pre-MRNA trans-splicing molecule (RTM) molecules and their uses

US8735366B2 · kind B2 · utility

19Cited by

3References

19Claims

0Family size

Inventors

Johann Bauer · Ismaning, DE
Lloyd G. Mitchell · Durham, US

Key dates

Filing date	Jul 30, 2009
Grant date	May 27, 2014
Priority date	—
Expiry date	Oct 12, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2840/445
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to specific and markedly improved pre-mRNA trans-splicing molecule (RTM) molecules which are designed to correct specific genes expressed within cells to be targeted, and which are associated with epidermolysis bullosa, cystic fibrosis, pachyonychia congenital, and psoriasis or neurodermitis, as well as cancers of the skin. In particular, the RTMs of the present invention are genetically engineered to interact with a specific target pre-mRNA expressed in cells to be targeted so as to result in correction of genetic defects or reprogramming of gene expression responsible for a variety of different skin disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.